A recent study presented at the ASCO Genitourinary Cancers Symposium 2017 held in Orlando, Florida, US showed that antibiotic use in patients with metastatic renal cell carcinoma (mRCC) may dampen the efficacy of PD-1/PD-L1 inhibitors.
Patients with castration-resistant prostate cancer (CRPC) may be able to reduce treatment cost by taking low-dose abiraterone acetate with a low-fat breakfast as a study shows noninferiority of the regimen compared with standard dosing on an empty stomach.
Some patients with metastatic renal cell carcinoma (mRCC) who respond to PD-1/PD-L1 immunotherapy can have persistent clinical benefit after treatment discontinuation due to immune-related adverse events.
Postmenopausal obese women who intentionally lose weight may lower their risk of endometrial cancer, a recent observational study shows.
Investigators from Hong Kong, Macau and Shenzhen recently discovered that high expression of PD-L1 in Chinese patients with HER2-positive breast cancer is associated with poor survival. A significantly poorer survival rate was found in those who also had high levels of tumour infiltrating lymphocytes (TILs).
Women who received a false positive result on their previous mammogram were less likely to undergo timely subsequent screening than women who obtained a true negative result, a recent study showed.
Mortality rates of melanoma are predicted to fall by 2050, but the number of individuals dying from the disease will increase due to population growth and ageing.